High density lipoprotein complete list of trials: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
===VA-HIT Trial=== | ===VA-HIT Trial=== | ||
Objective: To conclude if changes in plasma lipid levels due to [[gemfibrozil]] is the cause for reduction in major cardiovascular events in VA-HIT trial. | * Objective: To conclude if changes in plasma lipid levels due to [[gemfibrozil]] is the cause for reduction in major cardiovascular events in VA-HIT trial. | ||
* Method: VA_HIT trial is a multicentered, randomized, double-blinded, placebo-controlled trial wherein 2531 patients with CAD along with LDL levels ≤140 mg/dL (mean 111 mg/dL) and HDL ≤40 mg/dL (mean 32 mg/dL) were randomly assigned to treatment with gemfibrozil or placebo. | |||
Method: VA_HIT trial is a multicentered, randomized, double-blinded, placebo-controlled trial wherein 2531 patients with CAD along with LDL levels ≤140 mg/dL (mean 111 mg/dL) and HDL ≤40 mg/dL (mean 32 mg/dL) were randomly assigned to treatment with gemfibrozil or placebo. | * Results: At one year the following findings were noted in the group treated with gemfibrozil: | ||
** Mean HDL-C level was higher by 6% | |||
Results: At one year the following findings were noted in the group treated with gemfibrozil: | ** 31% lower mean TG concentration | ||
* Mean HDL-C level was higher by 6% | ** Mean total cholesterol was 4% lower | ||
* 31% lower mean TG concentration | |||
* Mean total cholesterol was 4% lower | |||
At five years, the combined primary end point of cardiac death and non-fatal myocardial infarction occurred in 17.3% versus 21.7% in the placebo group. Acute coronary events reduced by 11% with gemfibrozil for every 5 mg/dL rise in HDL-C, but the reduction was independent of changes in LDL-C and triglyceride levels. | At five years, the combined primary end point of cardiac death and non-fatal myocardial infarction occurred in 17.3% versus 21.7% in the placebo group. Acute coronary events reduced by 11% with gemfibrozil for every 5 mg/dL rise in HDL-C, but the reduction was independent of changes in LDL-C and triglyceride levels. |
Revision as of 01:09, 17 April 2013
High Density Lipoprotein Microchapters |
Diagnosis |
---|
Treatment |
Clinical Trials |
Case Studies |
High density lipoprotein complete list of trials On the Web |
American Roentgen Ray Society Images of High density lipoprotein complete list of trials |
High density lipoprotein complete list of trials in the news |
Risk calculators and risk factors for High density lipoprotein complete list of trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Landmark Trials
VA-HIT Trial
- Objective: To conclude if changes in plasma lipid levels due to gemfibrozil is the cause for reduction in major cardiovascular events in VA-HIT trial.
- Method: VA_HIT trial is a multicentered, randomized, double-blinded, placebo-controlled trial wherein 2531 patients with CAD along with LDL levels ≤140 mg/dL (mean 111 mg/dL) and HDL ≤40 mg/dL (mean 32 mg/dL) were randomly assigned to treatment with gemfibrozil or placebo.
- Results: At one year the following findings were noted in the group treated with gemfibrozil:
- Mean HDL-C level was higher by 6%
- 31% lower mean TG concentration
- Mean total cholesterol was 4% lower
At five years, the combined primary end point of cardiac death and non-fatal myocardial infarction occurred in 17.3% versus 21.7% in the placebo group. Acute coronary events reduced by 11% with gemfibrozil for every 5 mg/dL rise in HDL-C, but the reduction was independent of changes in LDL-C and triglyceride levels.